Abstract
SUMMARY Elderly patients constitute a substantial proportion of patients with advanced NSCLC. Several unresolved issues surround the treatment of elderly patients with NSCLC, including under-representation in clinical trials, the definitions of fit and unfit patients and the appropriate age cut-off for this population. Taken together, these factors have a large impact on the treatment of elderly patients with advanced NSCLC. An urgent need exists to develop new strategies for clinical trial design that may lead to improved outcomes in these patients. This review will address the existing barriers and controversies in the management of advanced NSCLC in the elderly, focusing on cytotoxic chemotherapy regimens. Results of clinical trials conducted in the elderly and those from planned subset analyses for age-unspecified trials will be provided, with a focus on recently reported studies. Outcomes from population databases reporting on this population in a nonclinical trial setting will be reviewed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
